Ken Saijo

The G8 screening tool enhances prognostic value to ECOG performance status in elderly cancer patients: A retrospective, single institutional study

Masahiro Takahashi, Masanobu Takahashi, Keigo Komine et al. · PLoS ONE · 2017 · 109 citations · Full text

Phase II trial of combination treatment with paclitaxel, carboplatin and cetuximab (PCE) as first-line treatment in patients with recurrent and/or metastatic squamous cell carcinoma of the head and neck (CSPOR-HN02)

Makoto Tahara, Naomi Kiyota, Tomoya Yokota et al. · Annals of Oncology · 2018 · 92 citations · Full text

IL-4 blockade alters the tumor microenvironment and augments the response to cancer immunotherapy in a mouse model

Shuku-ei Ito, Hidekazu Shirota, Yuki Kasahara et al. · Cancer Immunology Immunotherapy · 2017 · 75 citations · Full text

Immune Evasion, Tumor Immunology, Cancer Immunosurveillance +12

Romidepsin (<scp>FK</scp>228) and its analogs directly inhibit phosphatidylinositol 3‐kinase activity and potently induce apoptosis as histone deacetylase/phosphatidylinositol 3‐kinase dual inhibitors

Ken Saijo, Tadashi Katoh, Hideki Shimodaira et al. · Cancer Science · 2012 · 54 citations · Full text

Pi3k Inhibitors, Apoptosis, Cell Death +21

Biochemical, biological and structural properties of romidepsin (<scp>FK</scp>228) and its analogs as novel <scp>HDAC</scp>/<scp>PI</scp>3K dual inhibitors

Ken Saijo, Jin Imamura, Kôichi Narita et al. · Cancer Science · 2014 · 38 citations · Full text

Pharmaceutical Science, Chemoprevention Strategy, Chemical Biology +20